Antineoplastic drug resistance and breast cancer.
Morrow
C S
CS
Medical Breast Cancer Section, National Cancer Institute, Bethesda, Maryland 20892.
Cowan
K H
KH
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000477:Alkylating Agents / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002352:Carrier Proteins / Q000378:metabolism*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D004351:Drug Resistance / Q000502:physiology; D005260:Female; D005982:Glutathione Transferase / Q000378:metabolism; D006801:Humans; D008562:Membrane Glycoproteins / Q000378:metabolism*; D006899:Mixed Function Oxygenases / Q000378:metabolism
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000477:Alkylating Agents; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D005982:Glutathione Transferase; D004264:DNA Topoisomerases, Type I